Arcturus Therapeutics Holdings Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.arcturusrx.com

Earnings Score
Moat Score

Market Cap $507.07M
PE -8
Debt $NaN
Cash $294.06M
EV $NaN
FCF -$61.62M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$62.64M
EBIT	-$62.38M
ROE	-24%
ROA	-17%
FCF	-$61.62M
Equity	$261.87M
Growth Stability	1
PE	-8.09
PEG	-8.22
PB	1.94
P/FCF	-8.23
P/S	3.16
Price/Cash	0.58
Net Margins	-39%
Op. Margins	-39%
Earnings CAGR	0%
Sales Growth YoY	-8%
Sales Growth QoQ	-16%
Sales CAGR	88%
FCF CAGR	-0%
Equity CAGR	73%
Earnings Stability	-0.48
Earnings Growth YoY	-57%

Earnings Growth QoQ	-60%
Earnings CAGR 5Y	1%
Sales CAGR 5Y	119%
FCF CAGR 5Y	-1%
Equity CAGR 5Y	35%
Earnings CAGR 3Y	145%
Sales CAGR 3Y	145%
FCF CAGR 3Y	-4%
Equity CAGR 3Y	16%
Market Cap	$507.07M
Revenue	$160.40M
Assets	$370.65M
Cash	$294.06M
Shares Outstanding	26.95M
Earnings Score	6%
Moat Score	2%
Working Capital	261.36M
Current Ratio	4.76
Shares Growth 3y	1%
Equity Growth QoQ	1%
Equity Growth YoY	-6%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-COV19.

SEC Filings

Direct access to Arcturus Therapeutics Holdings Inc. (ARCT) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Arcturus Therapeutics Holdings Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Arcturus Therapeutics Holdings Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 0%

Stability -48%

loading chart...

Arcturus Therapeutics Holdings Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Arcturus Therapeutics Holdings Inc..

Years

Calculation mode

= -$604M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$62M	-$61M	-$61M	-$61M	-$61M	-$61M	-$61M	-$60M	-$60M	-$60M	-$60M	-$599M
DCF		-$56M	-$51M	-$46M	-$42M	-$38M	-$34M	-$31M	-$28M	-$25M	-$23M	-$231M
Value	-$604M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-138%	-125%	-756%	-2K%	5%	-18%	-39%
ROA	-	-31%	-15%	-52%	3%	-6%	-17%
ROE	-	-101%	-18%	-89%	3%	-11%	-24%

Bad Net Margins (-39.32%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-2.13	-0.37	-0.46	2.5	-	-
Debt over Equity	0.73	0.6	0.04	0.28	0.22	-	-
Growth Stability	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	32%	-54%	30%	2K%	-19%	119%
Earnings YoY growth	-	19%	178%	182%	-105%	-418%	1%
Equity YoY growth	-	89%	1K%	-42%	18%	3%	35%
FCF YoY growth	-	-67%	514%	210%	-118%	-187%	-1%